Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Q3 2022 Earnings Presentation
14 slides from Abcellera Biologics's earnings presentation, Nov 8, 2022
Slide 1: Q3 2022 Business Update
Exhibit 99.2 rAblellera Q3 2022 BUSINESS UPDATE NOVEMBER 8, 2022 Exhibit 99.2
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently av
Slide 3: 2022 Business Update Summary
03 2022. BUSINESS UPDATE SUMMARY 10 YEARS AT THE CUTTING EDGE OF ANTIBODY DISCOVERY $868M in cash, cash equivalents & marketable securities 164 cumulative programs under contract cumulative programs started 7 molecules in the clinic
Slide 4: Create value by powering innovation, capture value through shared success
CREATE VAL BY POWERING INNOVATION CAPTURE UAL THROUGH SHARED SUCCESS. PARTNER-INITIATED PROGRAMS TECHNOLOGY-DEVELOPMENT Discovery Co-Development program pre-partnred program Programs
Slide 5: Partnerships: discovery programs advance into preclinical and clinical development
PARTNERSHIPS 2 DISCOVERY PROGRAMS ADVANCE INTO PRECLINICAL AND CLINICAL DEVELOPMENT REGENERON undisclosed FIRST candidate to advance into further preclinical development GPCR target 4targets 9' multi-year multiple indications 1 MOLECULE. 1. ENTERED THE CLINIC Alzheimer's Disease
Slide 6: Partnerships and internal platforms: T-cell engager and GPCR programs
PARTNERSHIPS 2 DISCOVERY PROGRAMS ADVANCE INTO PRECLINICAL AND CLINICAL DEVELOPMENT REGENERON undisclosed FIRST candidate to advance into further preclinical development GPCR target 4targets 9' multi-year multiple indications 1 MOLECULE. 1. ENTERED THE CLINIC Alzheimer's Disease T-Cell engager platg
Slide 7: Q3 2022 Financial Update
Q3 2022 Financias update
Slide 8: Strong portfolio growth
Strong portfolio growth Cumulative of program starts cumulative of moleculas in the clinic total of program under contract WITHOUT downstream participation WITH downstream participation total of discovery partners 38 Chart Chart Note: Showing year-end figures except for most recent quarter. Historic
Slide 9: Molecules in the clinic
Now 7 molecules in the clinic MOLECULE STAGE PARTNER THERAPEUTIC AREA PROGRAM TYPE bamlanivimab Marketed, Emergency Use (LY-CoV555) Authorization (EUA) SZeer infectious disease - COVID-19 bebtelovimab Marketed, Emergency Use (LY-CoV1404) Authorization (EUA) infectious disease - COVID-19 AbCellera Di
Slide 10: $101.4M total revenue, driven by royalties for bebtelovimab
$101.4M total revenue, driven by royalties for bebtelovimab Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES Chart
Slide 11: Operating expenses reflect ongoing investments
Operating expenses reflect ongoing investments. Operating Expenses USD RESEARCH & DEVELOPMENT (BAR CHART) SALES & MARKETING (BAR CHART) GENERAL & ADMIN (BAR CHART) FINANCIALS Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 11
Slide 12: Net earnings of $26.6M
Net earnings of $26.6M: equivalent to $0.09 (basic) and $0.08 (diluted) per share Earnings USD NET EARNINGS (Bar chart) EARNINGS PER SHARE: BASIC (Bar chart) EARNINGS PER SHARE: DILUTED (Bar chart) COPYRIGHT©ABCELLERA Q3 2022 BUSINESS UPDATE FINANCIALS 12
Slide 13: Total cash, equivalents, and marketable securities
Nearly 900 million in total cash, equivalents, and marketable securities. Cash Flows USD [Bar chart] 13 COPYRIGHT © ABCELLERA Q3 2022 BUSINESS UPDATE FINANCIALS
Slide 14: Thank You
THANK YOU Q3 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 14